A whopping 83 percent of Mylan shareholders voted down the company’s astronomical executive compensation packages. But a majority of shareholders still supports most of the company’s beleaguered directors, according to fresh filings with the US Securities and Exchange Commission.

Those tallies, however, were revealed yesterday in a public filing with the SEC—and they’ve reignited calls for resignations and reform.

The vote breakdown shows that shareholders were overwhelmingly against the compensation packages—with 83 percent voting against them in the “Say-On-Pay” vote. However, most of the board of directors managed to garner majority support for their positions on the board. Only Wendy Cameron, the compensation chair, had less than a majority of support: only about 44 percent of the nearly 400 million votes favored her maintaining the position.

CEO Heather Bresch, who has become the public face of the company after appearing for media interviews and defending EpiPen pricing before Congress, was well supported: about 72 percent of the votes were in her favor.

Chairman Robert Coury also fared pretty well. He sparked outrage when the company revealed that he pocketed $97 million last year and was reported as having said (in a paraphrase) that critics of the company can “ go copulate with themselves .” About 66 percent of shareholders voted to keep him on the board.

Despite the majority support—which is well over what the board members needed to maintain their positions—some of the minority shareholders are still calling for change.

In a letter to Mylan (PDF), the shareholders that led the campaign to oust the board wrote that they considered the 56-percent vote against Cameron enough to call for her immediate resignation. And the 83-percent vote against the pay plans “effectively delivered a vote of ‘no confidence’ in Mylan’s entire Board of Directors.” They also called for Coury to step down and for the board to be reconstituted.

They wrote:

As long-term shareowners, we believe Mylan’s independent directors must act swiftly—or risk further erosion in shareowner confidence and value. Mylan’s share price is already down nearly 50 percent since its April 2015 peak, and the company remains under legal, regulatory, and public scrutiny for its EpiPen pricing practices.

They also called for governance changes to make ousting the board easier in the future, and they noted that about 90 percent of S&P 500 companies have majority voting policies in place. “There is no defensible rationale for Mylan’s current policy requiring a supermajority vote to remove directors,” they wrote.

Elections matter. Oversight matters. Accountability matters. This is simple. Shareowners cast majority or near-majority votes against several directors. By keeping them in the boardroom, Mylan would be yet again ignoring the very shareowners it is supposed to represent. Continuing down this path will only further undermine investor confidence.

The letter was co-authored by New York City Comptroller Scott Stringer, who oversees New York City’s pensions, which own more than 1.1 million shares of Mylan. In a statement e-mailed to Ars, he added:

When contacted by Ars, Mylan declined to comment on the shareholder letter and the calls for resignation. Instead, the company pointed to a statement in the SEC filing that reads: